The first ever phase III trials for multidrug-resistant TB (MDR-TB) finally yielded results. Treatment Action Group (TAG), ACTION, and the Drug-Resistant TB Treatment Scale-up Action Team (DR-TB STAT) presented the results in a webinar held on 12 December 2017. The webinar explored implications for the field, from the delamanid C213 trial and the STREAM trial to evaluate the shorter regimen for MDR-TB.
Dr. Francesca Conradie, Wits University
Dr. Carole Diane Mitnick, Harvard Medical School
Marcus Low, Spotlight
Mandy Slutsker, ACTION
Moderator: Erica Lessem, TAG’s Deputy Executive Director – TB Programs
To review the thoughtful presentations on the implications of the results, as well as the insightful questions posed to the presenters, visit the TAG website, where you can find the recorded webinar, transcript, presentations, and handouts.
Source: Treatment Action Group